Diabetic ketoacidosis does not precipitate haemolysis in patients with the Mediterranean variant of glucose-6-phosphate dehydrogenase deficiency.

Shalev, Oded; Wollner, A; Menczel, J

doi:10.1136/bmj.288.6412.179

Cited by 26 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a G6PD-deficient subject, hemolysis may occur as a result of ingestion of various drugs, ingestion of specific food substances and commonly, infection. None of the above-mentioned history could be detailed causes of G6PD deficiency in diabetic subjects could be because of hypoglycaemia [1], ketoacidosis in the African [3,4], but not Mediterranean variant of G6PD [5], and following administration of metformin [6] or glibenclamide [7]. In the present case, the patient was not on any oral hypoglycemic medication.…”

Section: Discussionmentioning

confidence: 81%

Glucose 6 Phosphate Dehydrogenase Deficiency Unmasked by Diabetic Ketoacidosis: An Underrated Phenomenon

Agarwal

Nayak

Patil

et al. 2013

JCDR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 81%

Glucose 6 Phosphate Dehydrogenase Deficiency Unmasked by Diabetic Ketoacidosis: An Underrated Phenomenon

Agarwal

Nayak

Patil

et al. 2013

JCDR

View full text Add to dashboard Cite

“…The list of drugs that should be avoided in G6PD deficiency has grown longer since the discovery of G6PD deficiency in the 1950s. However, a more recent analysis has shown that the concurrent infection may have been an important confounding factor for many drugs [60]. Commonly used drugs likely to induce hemolytic anemia in G6PD deficiency include primaquine, sulphamethoxazole, dapsone, nalidixic acid and nitrofurantoin [61].…”

Section: Clinical Application Of Pharmacogeneticsmentioning

confidence: 98%

Adverse Drug Reactions and Pharmacogenomics: Recent Advances

Alfirevic

Pirmohamed

2007

Personalized Medicine

View full text Add to dashboard Cite

The concept of pharmacogenomics, the study of how variation in the human genome affects response to drugs, attracts attention from clinicians and the pharmaceutical industry alike. The aim is to distinguish, using appropriate genetic tests, individuals who may be harmed by certain drugs from those who may benefit from them. Adverse drug reactions cause significant morbidity and mortality and incur a large cost to healthcare systems. Pharmacogenomics may help in the prediction and prevention of adverse reactions to drugs. While some recent studies (e.g., abacavir hypersensitivity) have shown strong associations with single genetic factors, whether these represent the exceptions rather than the rule is unclear. Further studies on adverse drug reaction pharmacogenetics are needed - these should be adequately powered and utilize the most appropriate study design that allows for an evaluation of both genetic and environmental factors. For pharmacogenetic testing to become acceptable in clinical practice, it is important that such studies are also able to provide evidence of clinical validity and clinical utility.

show abstract

“…pneumonia, hepatitis A and B, and typhoid fever) or oxidant drugs, or may be precipitated by diabetic ketoacidosis, myocardial infarction and strenuous physical exercise. 185,186 A list of the drugs which may cause haemolysis in G6PD-deficient individuals (Table 65.9) 187 can be obtained from: http://www.g6pd.org/favism/english/index.mv. A drug which is deemed to be safe for some G6PD-deficient individuals may cause haemolysis in others due to the heterogeneity of the underlying genetic variants.…”

Section: Acute Haemolytic Anaemiamentioning

confidence: 99%